About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Combining Chemotherapy With Gemtuzumab Ozogamicin can Improve Outcome of Bone Marrow Transplantation in High-Risk Leukemia

by Kathy Jones on November 17, 2013 at 8:55 PM
Font : A-A+

 Combining Chemotherapy With Gemtuzumab Ozogamicin can Improve Outcome of Bone Marrow Transplantation in High-Risk Leukemia

A new study conducted by researchers at St Jude Children's Research Hospital that has been published in the journal Cancer suggests that the outcome of bone marrow transplantation in some children diagnosed with high-risk acute myeloid leukemia (AML) can be improved by combining conventional chemotherapy with gemtuzumab ozogamicin (GO).

For young AML patients with suitable bone marrow donors, transplantation offers the best chance of a cure. Being free of even low levels of detectable cancer cells prior to transplantation is associated with better patient survival. This analysis found that combination therapy helped to eliminate minimal residual disease (MRD) in young AML patients who initially had a poor response to chemotherapy. By reducing MRD levels prior to transplantation, it is likely that GO contributed to the excellent outcome of these patients, researchers said.

Advertisement

The drug, trade named Mylotarg, received accelerated approval from the U.S. Food and Drug Administration in 2000 for treatment of AML in adults. The drug was voluntarily withdrawn in 2010 following questions about its safety and efficacy. Since then several studies conducted while the drug was authorized reported promising results in adults with AML. Those reports prompted this analysis of pediatric AML patients who received GO in a clinical trial conducted while the drug was available.

Researchers said the results add to evidence that both adults and children battling AML may benefit from treatments that use a similar mechanism as GO to combat AML. The drug was not associated with severe toxicity in this or other recent studies.
Advertisement

Unlike traditional chemotherapy that kills rapidly dividing cells, both malignant and healthy, GO was designed to kill more selectively. The drug works by targeting a protein carried on the surface of about 90 percent of AML cells. Work has begun on new strategies, including antibody-based therapies, that target the same AML surface protein, said the study's senior author Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Department of Oncology.

AML is diagnosed in about 500 children annually and accounts for about 20 percent of childhood leukemia. The disease affects white blood cells.

"Currently there are few options for AML patients who relapse or do not respond to conventional therapy," said first author Carol O'Hear, M.D., Ph.D., a St. Jude postdoctoral oncology fellow. Added Rubnitz: "Without new agents, it is unlikely we will be able to improve pediatric AML survival beyond current levels of about 70 percent. The results of this and earlier studies make a strong case that some patients benefit from this targeted therapy, which has us looking for new ways to take aim at the same protein."

This study involved a subset of patients enrolled in a clinical trial of pediatric AML called AML02. Altogether, 232 children with AML enrolled in the six-year, multicenter trial that ended in 2008. A total of 46 patients received GO alone or in combination with conventional chemotherapy.

For this analysis, researchers wanted to know if GO was associated with reduced MRD. Patients were considered free of MRD if less than one cancer cell could be detected in 1,000 normal bone marrow cells.

Seventeen patients received GO alone when MRD was detected after two rounds of chemotherapy with the drugs cytarabine, daunorubicin and etoposide. After GO treatment, leukemia declined in 14 of the 17 patients and fell to undetectable levels in 13 patients.

An additional 29 patients received GO as part of their second round of three-drug chemotherapy. All had levels of residual disease that indicated a poor initial response to chemotherapy alone, including nine with MRD levels of 25 percent or more. Residual disease fell to undetectable levels in four of the nine patients following combination therapy.

Malignant cells fell to undetectable levels in 45 percent, or nine of the remaining 20 patients whose second round of treatment included GO plus chemotherapy. The patients all had MRD of between 1 and 25 percent after the first round of chemotherapy.

The overall five-year survival level of the 20 patients was 55 percent, compared to 36 percent for 22 patients with similar MRD who received chemotherapy alone. The survival difference between the two groups was not statistically significant, but investigators said the results point to a possible benefit of GO treatment for some pediatric AML patients whose cancer remained following chemotherapy. The 22 patients were treated early in AML02 before the protocol was revised to expand the use of GO. The revision followed evidence that the drug was well tolerated by the young AML patients.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Bone Marrow Aspiration and Biopsy Leucopenia / Leukopenia Infantile Cortical Hyperostosis Chronic Lymphocytic Leukemia Hodgkins Lymphoma Non-Hodgkins Lymphoma Chemotherapy Chemotherapy Drugs Multiple Myeloma Peritoneal Cancer 

Recommended Reading
Leukemia
Encyclopedia section of medindia gives general information about Leukemia...
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess ......
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving ......
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is ......
Bone Marrow Aspiration and Biopsy
Bone marrow biopsy and aspiration is the removal of some bone marrow tissue for diagnosis and manage...
Chemotherapy
‘Chemo’ means medicine or ‘drug’; ‘therapy’ means ‘treatment’. Chemotherapy refers to the use of cy...
Chemotherapy Drugs
Chemotherapy drugs perform like ‘magic bullets’ to destroy cancer cells in the body....
Hodgkins Lymphoma
Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by c...
Infantile Cortical Hyperostosis
Infantile Cortical Hyperostosis is a disease of unknown cause, where bizarre thickening of the corti...
Leucopenia / Leukopenia
Leucopenia / Leukopenia is a decrease in the number of total white blood cells found in blood. The n...
Multiple Myeloma
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Meh...
Non-Hodgkins Lymphoma
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of ....
Peritoneal Cancer
Peritoneal cancer is a rare cancer that develops in the peritoneum. Peritoneal cancers may be primar...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use